country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-141602

Copy Link Print Information

Pinatuzumab vedotin

(Synonyms: anti-CD22-vc-MMAE; DCDT2980S)

Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1313706-14-7

Speicherung:

-80°C, protect from light

Pinatuzumab vedotin Chemical Structure

CAS. Nr.: 1313706-14-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- In Vivo
- Clinical Trial
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vivo

Pinatuzumab vedotin (5 mg/kg, i.v., one single dose) displays systemic Monomethyl auristatin E (MMAE) at about 5-fold higher blood concentration compared to plasma concentration once MMAE reached a pseudo-equilibrium in mouse whilst systemic MMAE from blood and plasma concentration showed a 1.65-fold difference in rat^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1313706-14-7
Appearance Liquid
Color Colorless to light yellow
SMILES

[Pinatuzumab vedotin]
Synonyms

anti-CD22-vc-MMAE; DCDT2980S
Versand

Shipping with dry ice.
Speicherung

-80°C, protect from light

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (264 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. [Content Brief]

[2]. Yip, V., et al., (2024). Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species. Xenobiotica; the fate of foreign compounds in biological systems, 54(8), 511–520. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager